Abstract: A mobile communication system includes a plurality of base stations and a mobile station communicating with the base station through a wireless channel. The system comprises a part which measures an amount of information transferred between the base station and the mobile station and a comparator which compares the measured amount of information with first and second threshold values corresponding to a currently used wireless channel. A wireless channel changeover part changes the current wireless channel to a wireless channel with a transmission capability higher or lower than that of the current wireless channel when the measured amount of information is above the first threshold value or below the second threshold value, respectively.

Abstract: This invention provides for a composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of inhibiting the proliferation of cancer cells. This invention also provides a method of treating cancer with a composition in an amount effective to result in an amount in apoptosis of the cells. This invention also provides a method of inhibiting the proliferation of virally infected cells. This invention also provides for a method of treating a virally-infected subject with a composition in an amount effective to result in apoptosis of the cells. This invention also provides for pharmaceutical compositions.

Abstract: The present invention provides a mammalian CD40-associated protein (CAP), a nucleic acid molecule encoding the CAP and antibodies specific for the CAP. The invention further provides a substantially purified human CAP-1 and a nucleic acid molecule encoding human CAP-1. The invention also provides screening assays for identifying an agent that effectively alters the association of a CAP with a second molecule, which can bind to the CAP. In addition, the invention provides methods for identify a CAP agonist or CAP antagonist that can increase or decrease, respectively, the level of expression of the CAP in a cell. Such an effective agent, agonist or antagonist can modulate a function of a cell such as a humoral immune response or cell growth. The invention also provides methods of detecting a CAP in a sample by detecting the CAP or a nucleic acid molecule encoding the CAP. Such methods can be used to diagnose a pathology that is characterized by an increased or decreased level of a CAP in a cell.

Abstract: A handover type judgement scheme for a CDMA mobile communication system which is capable of judging an appropriate type of handover from multiple types of handover available. At the mobile station, one type of handover for which a handover start condition is weakest among available types of handover is judged. Then, whether the handover start condition for that one type of handover is satisfied or not is checked, and each base station for carrying out that one type of handover is notified when the handover start condition for said one type of handover is satisfied.

Abstract: The present invention provides a mammalian CD40-associated protein (CAP), a nucleic acid molecule encoding the CAP and antibodies specific for the CAP. The invention further provides a substantially purified human CAP-1 and a nucleic acid molecule encoding human CAP-1. The invention also provides screening assays for identifying an agent that effectively alters the association of a CAP with a second molecule, which can bind to the CAP. In addition, the invention provides methods for identify a CAP agonist or CAP antagonist that can increase or decrease, respectively, the level of expression of the CAP in a cell. Such an effective agent, agonist or antagonist can modulate a function of a cell such as a humoral immune response or cell growth. The invention also provides methods of detecting a CAP in a sample by detecting the CAP or a nucleic acid molecule encoding the CAP. Such methods can be used to diagnose a pathology that is characterized by an increased or decreased level of a CAP in a cell.

Abstract: A mobile station is provided for autonomously detect an abrupt change of a propagation environment of a radio wave signal from a base station for servicing a peripheral cell and immediately executing a peripheral cell search. In order to execute a received signal strength indication plural times within one period of the peripheral cell search, the mobile station operates to set a cell search execution period &Dgr;t1 to a timer of a peripheral cell search controller and a RSSI measuring execution period &Dgr;t2 to a timer. The RSSI measuring unit operates to measure the RSSI in the receiving band at each RSSI measuring execution period &Dgr;t2 and immediately execute the peripheral cell search when the peripheral cell search controller determines that the RSSI has greatly varied.

Abstract: In the method of handover control, when a mobile station recognizes that the mobile station has moved to an overlapping area, the mobile station notifies this fact to a network side and in response the network side sets up only a communication channel between a handover target base station and an exchange station for controlling that handover target base station, without setting up a radio channel between the handover target base station and the mobile station, while continuing the communication by not releasing the communication channel between the currently located base station and the exchange station and the radio channel between the currently located base station and the mobile station, so that it becomes possible to reduce a transmission control load for transmission between the base station and the exchange station as well as a control load for controlling the exchange station itself.

Abstract: The present invention provides a mammalian CD40-associated protein (CAP), a nucleic acid molecule encoding the CAP and antibodies specific for the CAP. The invention further provides a substantially purified human CAP-1 and a nucleic acid molecule encoding human CAP-1. The invention also provides screening assays for identifying an agent that effectively alters the association of a CAP with a second molecule, which can bind to the CAP. In addition, the invention provides methods for identify a CAP agonist or CAP antagonist that can increase or decrease, respectively, the level of expression of the CAP in a cell. Such an effective agent, agonist or antagonist can modulate a function of a cell such as a humoral immune response or cell growth. The invention also provides methods of detecting a CAP in a sample by detecting the CAP or a nucleic acid molecule encoding the CAP. Such methods can be used to diagnose a pathology that is characterized by an increased or decreased level of a CAP in a cell.

Abstract: A downlink transmission power control scheme for a mobile communication system using the site diversity, which carries out a primary downlink transmission power control using a primary control signal which is transmitted from the mobile station and terminated at each base station, and an additional downlink transmission power control using additional control signals which are transmitted from the base station control station to the base stations. The additional downlink transmission power control may also use a secondary control signal which is transmitted from the mobile station and terminated at the base station control station. The primary downlink transmission power control can be carried out during a non-site diversity period while the additional downlink transmission power control is carried out during the site diversity period, or the primary downlink transmission power control and the additional downlink transmission power control can be both carried out during the site diversity period.

Abstract: The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b, each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or fragment of a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS.

Abstract: The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b, each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS.

Abstract: The present invention provides methods for detecting an interaction among proteins involved in regulating cell death. The invention also provides a drug screening assay useful for identifying agents that alter an interaction among proteins involved in controlling cell death. The invention further provides a method for identifying novel proteins that are involved in a cell death pathway.

Abstract: The present invention provides nucleotide sequences encoding proteins and fragments thereof that bind to Bcl-2-related proteins. The invention also provides a Bcl-2-associated protein (BAP) such as Bcl-2-associated protein-1 (BAP-1), which binds to Bcl-2. The invention also provides antibodies that specifically bind to a BAP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BAP such as BAP-1 or Raf-related protein with a Bcl-2-related protein and methods for detecting agents that induce dissociation of a bound complex formed by the association of a BAP and a Bcl-2-related protein. The invention further provides methods for modulating the activity of a Bcl-2-related protein in a cell by introducing into the cell a nucleic acid encoding a BAP or by introducing into the cell an antisense nucleotide sequence, which is complementary to a region of a gene encoding a BAP.

Abstract: The present invention provides nucleotide sequences encoding proteins and fragments thereof that bind to Bcl-2-related proteins. The invention also provides a Bcl-2-associated protein (BAP) such as Bcl-2-associated protein-1 (BAP-1), which binds to Bcl-2. The invention also provides antibodies that specifically bind to a BAP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BAP such as BAP-1 or Raf-related protein with a Bcl-2-related protein and methods for detecting agents that induce dissociation of a bound complex formed by the association of a BAP and a Bcl-2-related protein. The invention further provides methods for modulating the activity of a Bcl-2-related protein in a cell by introducing into the cell a nucleic acid encoding a BAP or by introducing into the cell an antisense nucleotide sequence, which is complementary to a region of a gene encoding a BAP.

Abstract: The present invention provides nucleotide sequences encoding proteins and fragments thereof that bind to Bcl-2-related proteins. The invention also provides a Bcl-2-associated protein (BAP) such as Bcl-2-associated protein-1 (BAP-1), which binds to Bcl-2. The invention also provides antibodies that specifically bind to a BAP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BAP such as BAP-1 or Raf-related protein with a Bcl-2-related protein and methods for detecting agents that induce dissociation of a bound complex formed by the association of a BAP and a Bcl-2-related protein. The invention further provides methods for modulating the activity of a Bcl-2-related protein in a cell by introducing into the cell a nucleic acid encoding a BAP or by introducing into the cell an antisense nucleotide sequence, which is complementary to a region of a gene encoding a BAP.

Abstract: The present invention provides mammalian protein tyrosine phosphatases, human PTP-BAS type 4, human PTP-BAS type 5a and mouse PTP-BAS type 5b, each of which is a Fas-associated protein (FAP), nucleic acid molecules encoding a PTP-BAS type 4 or a PTP-BAS type 5 and antibodies specific for a PTP-BAS type 4 or for a PTP-BAS type 5. The invention also provides methods for identifying FAP's, which can associate with Fas and can modulate apoptosis. The invention also provides screening assays for identifying an agent that can effectively alter the association of a FAP with Fas and, therefore, can increase or decrease the level of apoptosis in a cell. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a PTP-BAS or fragment of a PTP-BAS or an antisense nucleotide sequence, which is complementary to a portion of a nucleic acid molecule encoding a PTP-BAS.

Abstract: A failure-free power source device memorizes the history of errors of a commercially available power source, monitors the stability of the power source on the basis of the history, directly outputs, when the power source remains stable for more than a predetermined period of time, an AC input as an AC output, and releases, when an error occurs in the power source, energy stored in an accumulator until a predetermined period of time expires to thereby output it as an AC output via an inverter.

Abstract: A human prohibitin gene, a protein coded for by said gene, a gene analysis reagent to be used with them, and a quantitative determination of prohibitin in a biological sample by an immunological technique with the use of an antihuman prohibitin antibody and a method for analyzing a prohibitin gene of a human tissue for the occurrence of mutation by the PCR method with the use of oligonucleotides having partial base sequences of said gene as primers.

Abstract: A method for discriminating a chemical/physical quantity comprises exposing a sensor array consisting of a plurality of sensor members exhibiting differing response ranges with respect to a chemical/physical quantity to stimulation and discriminating the cause of the stimulation from the order in which the sensor members produce lowest significant (discriminable) output levels.

Abstract: The present invention provides nucleotide sequences encoding proteins and fragments thereof that bind to Bcl-2-related proteins. The invention also provides a Bcl-2-associated protein (BAP) such as Bcl-2-associated protein-1 (BAP-1), which binds to Bcl-2. The invention also provides antibodies that specifically bind to a BAP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BAP such as BAP-1 or Raf-related protein with a Bcl-2-related protein and methods for detecting agents that induce dissociation of a bound complex formed by the association of a BAP and a Bcl-2-related protein. The invention further provides methods for modulating the activity of a Bcl-2-related protein in a cell by introducing into the cell a nucleic acid encoding a BAP or by introducing into the cell an antisense nucleotide sequence, which is complementary to a region of a gene encoding a BAP.